The Journal of Urology
Volume 183, Issue 5 , Pages 1678-1685 , May 2010

Marker Lesion Experiments in Bladder Cancer—What Have We Learned?

  • Ofer N. Gofrit

      Affiliations

    • Department of Urology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    • Corresponding Author InformationCorrespondence: Department of Urology, Hadassah University Hospital, P.O. Box 12000, Jerusalem 91120, Israel (telephone: +972-2-6776874; FAX: +972-2-6430929)
    • ,
  • Kevin C. Zorn

      Affiliations

    • Department of Surgery, Section of Urology, University of Chicago Medical Center, Chicago, Illinois
    • ,
  • Sergey Shikanov

      Affiliations

    • Department of Surgery, Section of Urology, University of Chicago Medical Center, Chicago, Illinois
    • ,
  • Gary D. Steinberg

      Affiliations

    • Department of Surgery, Section of Urology, University of Chicago Medical Center, Chicago, Illinois

Received 4 July 2009

References 

  1. Koontz WW, Prout GR, Smith W, et al. The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder. J Urol. 1981;125:307
  2. Heney NM, Koontz WW, Barton B, et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol. 1988;140:1390
  3. Calais daSilva F, Denis L, Bono A, et al. Intravesical chemoresection with 4′-epi-doxorubicin in patients with superficial bladder tumors. Eur Urol. 1988;14:207
  4. Cumming JA, Kirk D, Newling DW, et al. A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumour. Eur Urol. 1990;17:20
  5. Serretta V, Corselli G, Piazza B, et al. Intravesical therapy of superficial bladder transitional cell carcinoma with tumor necrosis factor-alpha: preliminary report of a phase I-II study. Eur Urol. 1992;22:112
  6. Fellows GJ, Parmar MK, Grigor KM, et al. Marker tumour response to Evans and Pasteur bacille Calmette-Guérin in multiple recurrent pTa/pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br J Urol. 1994;73:639
  7. Popert RJ, Goodall J, Coptcoat MJ, et al. Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin. Br J Urol. 1994;74:195
  8. Van derMeijden AP, Hall RR, Macaluso MP, et al. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours (Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897)). Eur Urol. 1996;29:199
  9. Bono AV, Hall RR, Denis L, et al. Chemoresection in Ta-T1 bladder cancer (Members of the EORTC Genito-Urinary Group). Eur Urol. 1996;29:385
  10. Brausi M, Campo B, Pizzocaro G, et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study. Urology. 1998;51:506
  11. Den Otter W, Dobrowolski Z, Bugajski A, et al. Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol. 1998;159:1183
  12. Stravoravdi P, Toliou T, Kirtsis P, et al. A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa. J Interferon Cytokine Res. 1999;19:221
  13. Mack D, Höltl W, Bassi P, et al. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol. 2001;165:401
  14. Newling DW, Hetherington J, Sundaram SK, et al. The use of valrubicin for the chemoresection of superficial bladder cancer—a marker lesion study. Eur Urol. 2001;39:643
  15. Malmström PU. A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int. 2002;89:681
  16. Gontero P, Casetta G, Maso G, et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol. 2004;46:339
  17. Gårdmark T, Carringer M, Beckman E, et al. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent stage Ta urothelial cell carcinoma of the bladder. Urology. 2005;66:527
  18. Serretta V, Galuffo A, Pavone C, et al. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions. Urology. 2005;65:65
  19. van derHeijden AG, Moonen PM, Cornel EB, et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol. 2006;176:1349
  20. Puri R, Palit V, Loadman PM, et al. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J Urol. 2006;176:1344
  21. Maffezzini M, Campodonico F, Canepa G, et al. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder. Eur Urol. 2007;51:956
  22. Sidi AA, Ohana P, Benjamin S, et al. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol. 2008;180:2379
  23. Hendricksen K, van derHeijden AG, Cornel EB, et al. Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol. 2009;27:337
  24. van derMeijden AP, Hall RR, Kurth KH, et al. Phase II trials in Ta, T1 bladder cancer (The marker tumour concept). Br J Urol. 1996;77:634
  25. Gofrit ON, Pode D, Lazar A, et al. Watchful waiting policy in recurrent Ta G1 bladder tumor. Eur Urol. 2006;49:303
  26. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1
  27. Oosterlinck W, Bono AV, Mack D, et al. Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions. Eur Urol. 2001;40:515
  28. van derMeijden AP. The use of the marker tumor concept in Ta, T1 bladder cancer: is it justified?. Urol Oncol. 2002;7:31
  29. Jain A, Phillips RM, Scally AJ, et al. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology. 2009;73:1083
  30. Sylvester RJ, van derMeijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466

 See Editorial on page 1667.

PII: S0022-5347(09)03403-X

doi: 10.1016/j.juro.2009.12.104

The Journal of Urology
Volume 183, Issue 5 , Pages 1678-1685 , May 2010

Article Tools

* Image Usage & Resolution